Tianbao

Tianbao Biopharmaceutical, a subsidiary of the formerly listed Dalian Tianbao Green Foods, was a Chinese pharmaceutical company specializing in the production of biochemical drugs derived from marine and animal sources. The company was best known for its manufacturing of heparin-based anticoagulants, including low molecular weight heparin sodium and heparin sodium injections. In addition to its cardiovascular portfolio, Tianbao produced chondroitin sulfate and other biological products aimed at treating joint disorders and inflammatory conditions. However, following the significant financial distress and eventual delisting of its parent company in 2020, Tianbao Biopharmaceutical's operations were severely impacted, leading to bankruptcy and liquidation proceedings.